• Apremilast has recently been approved by the European Commission for the treatment of active psoriatic arthritis and moderate to severe chronic plaque psoriasis.
OBJECTIVES
• This study was designed to estimate the budget impact following the introduction of apremilast in the treatment of adult patients in Italy with moderate to severe, chronic plaque psoriasis who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate, or psoralen and ultraviolet-A light (PUVA).
• Because apremilast is an available oral option for these patients before being treated with biological therapies, this analysis aims to verify whether the delay in treatment with biologicals might yield cost savings.
METHODS
• A budget impact model was adapted to the Italian setting using local epidemiological and cost data. The model was used to assess the financial impact of introducing apremilast to the market for the Italian National Health Service (NHS).
• The analysis was conducted over a 3-year time horizon considering year 2016 as baseline. Real data of market consumption (IMS 2014 data) were used, reflecting the budget holder's perspective, and a 2015 real-world study concerning the healthcare resource consumption related to each treatment was considered (apremilast, etanercept, infliximab, adalimumab, or ustekinumab).
• A total of ≈11,500 patients were considered as the model population at the first year (2016), with an assumed 5% to 7% annual growth rate: ≈12,200 patients at 2017 and ≈13,000 patients at 2018.
• Market penetration of apremilast was based on manufacturer assumptions ( Table 1 and Table 2 ). • Unit costs were generally taken from Italian standard sources (e.g., Gazzetta Ufficiale regional tariffs, Farmadati database), and annual drug costs were derived from the ex-factory gross prices based on current dosages. 2, 3, 4 Given that apremilast is not currently reimbursed by the Italian NHS, the cost of apremilast 30 mg BID was set at the UK NHS publicly available price ( Table 3) . • Frequency of screening and monitoring for each treatment was obtained from real-world data (administrative database analysis performed by Clicon S.r.l. [data on file]). Administration and physician visit costs are presented in Table 4 and Table 5 . • The total annual costs of monitoring tests are shown in Table 6 . 
RESULTS
• A total of ≈11,500 patients were considered as the model population in the first year, with an assumed 5% to 7% annual growth rate.
• The introduction of apremilast over the next 3 years, assuming a market share of 1% to 5%, 10% to 15%, and 15% to 20%, for the first, second, and third year, respectively, would lead to cost savings varying from a minimum of €10,080,000 to a maximum of €15,377,000 for the 3 years (Figures 1-3 ). • Assuming the maximum market share for apremilast of the ranges mentioned, results of the model are detailed in Table 7 .
Figure 1. Impact of Apremilast Introduction on Overall Psoriasis Cost
• In particular, drug savings account for 91% each year, whereas monitoring savings account for 3% and administration savings account for 6%. 
CONCLUSION
• This analysis suggests that the use of apremilast for the treatment of moderate to severe plaque psoriasis may represent a cost-saving option for the Italian NHS over the first 3 years of utilisation.
